Medexus Pharmaceuticals (TSE:MDP) Shares Up 2.4% - Still a Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) shot up 2.4% on Monday . The stock traded as high as C$3.19 and last traded at C$3.00. 55,522 shares changed hands during trading, a decline of 34% from the average session volume of 83,952 shares. The stock had previously closed at C$2.93.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$67.16 million, a PE ratio of 14.35 and a beta of 1.96. The company has a 50-day moving average of C$2.69 and a two-hundred day moving average of C$2.98.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.